clinical trial · NCT03748641
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
Janssen Research & Development, LLC·phase3·active not recruiting·n = 765
Castration-Resistant Prostatic CancerNiraparibAbiraterone AcetatePrednisonePlaceboNew Formulation of Niraparib and Abiraterone Acetate (AA)
brief summary
The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate plus prednisone (AAP) compared to AAP and placebo.
started
Jan 25, 2019
primary completion
Oct 8, 2021
completion
Feb 27, 2027
last updated
Jun 5, 2026
official title
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol